We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO Announces Immuno-Oncology Data Presentations at SITC 2018 Annual Meeting
Initial data from AMBER trial of TSR-022 (anti-TIM-3) in combination with TSR-042 (anti-PD-1) demonstrated clinical activity in patients who have progressed following anti-PD-1 treatment TSR-042 monotherapy demonstrated significant activity in patients with previously treated recurrent/advanced
View HTML
Toggle Summary TESARO Announces Third-Quarter 2018 Operating Results
ZEJULA® Q3 net sales totaled $63 million compared to $39 million for Q3 2017 Top-line results for PRIMA trial of ZEJULA monotherapy for first-line ovarian cancer patients regardless of BRCA mutation status anticipated in late 2019 Data presented at ESMO for TSR-042 indicate robust activity in
View HTML
Toggle Summary The Foundation for Women’s Cancer and TESARO Partner on the Race to End Women’s Cancer for 3rd Year
CHICAGO and WALTHAM, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- The Foundation for Women’s Cancer (FWC), the official foundation of the Society of Gynecologic Oncology (SGO), and TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the third year of their
View HTML
Toggle Summary TESARO Announces Achievement of ZEJULA Prostate Cancer Development Milestones by Janssen
WALTHAM, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced the achievement of development milestones that trigger an $18 million payment from Janssen Biotech Inc. (Janssen).
View HTML
Toggle Summary TESARO and Actress Cobie Smulders Launch Not on My Watch, a National Movement to Empower the Ovarian Cancer Community
Not on My Watch Aims to Shine a Light on the Importance of an Informed, Proactive Approach to Treatment Not on my watch logo WALTHAM, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, announced today the launch of Not on My Watch ,
View HTML
Toggle Summary TESARO Announces Data Presentations at ESMO 2018 Congress
Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancer PRIMA safety data for individualized niraparib dose regimen presented Top-line results for PRIMA trial of niraparib in first-line ovarian cancer regardless
View HTML
Toggle Summary TESARO to Announce Third-Quarter 2018 Financial Results on November 1, 2018
WALTHAM, Mass. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO) will announce third-quarter 2018 financial results on Thursday, November 1, 2018 , after the close of the U.S. financial markets. TESARO’s senior management team will host a conference call and live audio webcast at 4:15
View HTML
Toggle Summary TESARO Announces Data Presentations at the ESMO 2018 Congress
WALTHAM, Mass. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that data from six abstracts will be presented at the European Society for Medical Oncology (ESMO) Congress from October 19-23, 2018 in Munich, Germany .
View HTML
Toggle Summary TESARO Announces Data Presentations at the SITC 2018 Annual Meeting
WALTHAM, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that data from a total of five abstracts will be presented at the Society for Immunotherapy of Cancer ( SITC ) Annual Meeting from November 7-11, 2018 in
View HTML
Toggle Summary TESARO Announces Participation at Two Investor Conferences
WALTHAM, Mass. , Sept. 19, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:         The Cantor Global Healthcare Conference at the InterContinental
View HTML